Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The “mitochondrial ribosomal protein L21 pseudogene” refers to one or more non-functional, processed or duplicated genomic loci derived from the MRPL21 gene, which encodes the mitochondrial ribosomal protein L21, a component of the large 39S subunit of the mitochondrial ribosome[1][2][5][8]. These pseudogenes do not produce functional proteins and are considered genomic “fossils”; they typically result from gene duplication or retrotransposition events and may contain sequence homology with the parent gene MRPL21, but lack the ability to be translated into an active protein[2][5]. No structured role has been described for these pseudogenes in translation, disease, or drug response, and they are not considered therapeutic targets. It is possible, though rarely, for pseudogenes to have regulatory functions (e.g., non-coding RNA), but no such evidence exists for this specific pseudogene[2][5].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein L21 pseudogene (MRPL21P).